日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy

意大利含西妥昔单抗方案治疗头颈部鳞状细胞癌的成本效益分析

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2025.2503667
Ivanyi, Philipp; Bullement, Ash; Botticelli, Andrea; Perri, Francesco; Colombo, Giorgio L; Annibali, Viviana; Gandola, Anita; Naik, Jaesh; Schlichting, Michael; Pescott, Chris P
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden

瑞典一线治疗间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌成人患者中，洛拉替尼的成本效益分析

期刊:Applied Health Economics and Health Policy
影响因子:3.3
doi:10.1007/s40258-023-00807-7
Naik, Jaesh; Beavers, Norma; Nilsson, Fredrik O L; Iadeluca, Laura; Lowry, Chrissy
肺癌
肿瘤
肿瘤免疫
信号转导
ALK
淋巴瘤
细胞生物学
发表日期：2023
文献求助 收藏

Cost-effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia

亚胺培南/西司他丁/瑞巴坦治疗医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎的成本效益分析

期刊:Journal of Comparative Effectiveness Research
影响因子:2.5
doi:10.2217/cer-2022-0113
Naik, Jaesh; Dillon, Ryan; Massello, Matthew; Ralph, Lewis; Yang, Zhuo
肺炎
微生物学
发表日期：2023
文献求助 收藏

Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain

洛拉替尼治疗西班牙成人间变性淋巴瘤激酶阳性晚期非小细胞肺癌患者的成本效益分析

期刊:
影响因子:
doi:10.2147/CEOR.S415711
Presa, María; Vicente, David; Calles, Antonio; Salinas-Ortega, Laura; Naik, Jaesh; García, Luis F; Soto, Javier
信号转导
肺癌
肿瘤
淋巴瘤
细胞生物学
肿瘤免疫
发表日期：2023
文献求助 收藏

Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms

亚胺培南/西司他丁/瑞巴坦与粘菌素治疗碳青霉烯类耐药菌引起的革兰氏阴性菌感染的成本效益比较

期刊:Infectious Diseases and Therapy
影响因子:5.3
doi:10.1007/s40121-022-00607-x
Yang, Joe; Naik, Jaesh; Massello, Matthew; Ralph, Lewis; Dillon, Ryan James
炎症/感染
发表日期：2022
文献求助 收藏

Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms

更正：亚胺培南/西司他丁/瑞巴坦与粘菌素治疗碳青霉烯类耐药菌引起的革兰氏阴性菌感染的成本效益比较

期刊:Infectious Diseases and Therapy
影响因子:5.3
doi:10.1007/s40121-022-00660-6
Yang, Joe; Naik, Jaesh; Massello, Matthew; Ralph, Lewis; Dillon, Ryan James
炎症/感染
发表日期：2022
文献求助 收藏

Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

头孢洛扎/他唑巴坦与美罗培南治疗呼吸机相关性医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎患者的成本效益比较

期刊:Infectious Diseases and Therapy
影响因子:5.3
doi:10.1007/s40121-021-00436-4
Naik, Jaesh; Puzniak, Laura; Critchlow, Simone; Elsea, David; Dillon, Ryan James; Yang, Joe
肺炎
微生物学
发表日期：2021
文献求助 收藏